Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Triple Negative Breast Cancer Team Project
Team Project

Triple Negative Breast Cancer Team Project

333
Anderson, KarenArizona State University
Anderson, KarenArizona State University

No involved investigator sites defined.

40 biomarkers:1   NADH dehydrogenase 1a subcomplex, 10      NDUFA102   Protein-tyrosine phosphatase, mitochondrial 1      PTPMT13   Integrin beta-1      ITGB14   Mast/stem cell growth factor receptor      KIT5   DNA-directed RNA polymerase L, 7.6 kDa      POLR2L6   Ephrin-A5      EFNA57   Regulator of G-protein signaling 5      RGS58   TNFR superfamily member 6 (Ab1)      FAS9   Stomatin-like protein 2      STOML210   Signal transducer /activator of transcription 6      STAT611   Cysteine-rich protein 2 
Proteomics
Breast and Gynecologic Cancers Research
1

Triple negative breast cancers (TNBC), comprise 15-20% of breast cancers, and are associated with later stage at diagnosis, increased mortality, and occur more frequently in younger women where mammographic screening is less reliable. TNBCs are more likely to be diagnosed by physical exam than by mammographic screening. There is an unmet clinical need for biomarkers for the early detection of TNBC. Here, we are proposing the development of a plasma-based biomarker panel for the routine screening of women over the age of 40 for TNBC that can be used to identify women for further imaging.

The overall study design involves the identification of three distinct types of blood-based biomarkers: 1. Autoantibodies (Anderson/LaBaer) 2. Protein antigens (Li/Lampe; Zangar). 3. miRNA (Huebner/Croce). These biomarkers will be validated in a step-wise fashion using samples provided by the CEVCs and multi-institutional cohorts, with study design and evaluation by the DMCC. Aim 1. Verification of novel biomarkers for TNBC Aim 2. Validate the top biomarkers for TNBC using a diagnostic set of plasma. Aim 3. Determine the sensitivity, specificity, and positive predictive value of the top marker combinations found in aim 2 to distinguish TNBC from benign breast disease, and for the detection of ER+ and Her2+ breast cancer, using the EDRN Reference Set. Aim 4. Develop a phase III validation plan for testing the top biomarkers and biomarker combination for TNBC detection using prediagnostic sera from WHI, ROCA, and PLCO.
We will systematically compare existing TNBC biomarkers that have been identified from multiple laboratories, targeting protein antigens, autoantibodies, and miRNAs. These biomarkers will be validated in a step-wise fashion using samples provided by the CEVCs and multi institutional cohorts, with study design and evaluation by the DMCC. The individual and composite sensitivities and specificities of these biomarkers for the detection of TNBC and non-TNBC breast cancers will be evaluated. These studies will lead to the development of a phase III validation plan for testing the top biomarkers and biomarker combination for TNBC detection using prediagnostic sera from WHI, ROCA, and PLCO.

No datasets are currently associated with this protocol.


Announcement 10/27/2016

Thank you to everyone who contributed to the successful and productive EDRN Orientation Meeting in October. The next EDRN Steering Committee Meeting will take place in March 6-9, 2017 in Tempe, AZ. More information about this meeting will be available soon.

Announcement